ORIFARM GENERICS A/S: Financial statements 2020
CVR: 25674030
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 688,426,000 and a net result of DKK 145,514,000 compared with DKK 103,855,000 the year before. That is an increase of 26.3% compared with the year before. The profit margin was 21.1%. Equity in the 2020 report amounted to DKK 201,194,000. The solvency ratio was 44.1%. The company had 117 employees in the financial year.
- Revenue
- DKK 688,426,000
- Gross Profit
- DKK 274,178,000
- Profit/Loss
- DKK 145,514,000
- Equity
- DKK 201,194,000
- Total Assets
- DKK 455,784,000
- Employees
- 117
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 688.4 mio. | 274.2 mio. | 145.5 mio. | 201.2 mio. | 117 |
| 2019 | 545 mio. | 197 mio. | 103.9 mio. | 145.7 mio. | 99 |
| 2018 | 504.4 mio. | 162.7 mio. | 70.1 mio. | 116.8 mio. | 102 |
| 2017 | - | 172 mio. | 76.4 mio. | 86.8 mio. | 97 |
| 2016 | - | 169.9 mio. | 83.3 mio. | 60.4 mio. | 78 |
Official annual report
How creditworthy is ORIFARM GENERICS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ORIFARM GENERICS A/S has published its annual report for 2019. Revenue came to DKK 545,016,000, and the net result was DKK 103,855,000.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.